Rituximab for treatment of ocular inflammatory disease: a series of four cases
- 1Casey Eye Institute/Oregon Health & Science University, Portland, Oregon, USA
- 2Dayton VA Medical Center, Dayton, Ohio, USA
- 3Ohio State University Department of Ophthalmology, Columbus, Ohio, USA
- Dr J T Rosenbaum, Mail Code L467AD, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA; rosenbaj{at}ohsu.edu
- Accepted 31 October 2008
Abstract
Rituximab may be effective in the treatment of ocular inflammatory disease. Dosing is less frequent than many medications currently available. Four cases are reported, each of which appeared to have responded well to treatment with rituximab, although patient 2 was able to remain on a low dose of prednisone for only 2 months. The ongoing pilot study will hopefully provide additional insight into the benefit of rituximab for treatment of scleritis and idiopathic orbital inflammatory disease.
Footnotes
-
Funding: We are grateful for financial support from the Stan and Madelle Rosenfeld Family Trust.
-
Competing interests: JTR, EBS and PAK disclose a relationship with Genentech, in that Genentech is sponsoring the follow-up Phase I/II prospective study.
-
Ethics approval: Ethics approval was provided by the Institutional Review Board, Oregon Health & Science University.
-
Patient consent: Obtained.







